The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401)

被引：0
|
作者：
Small, Eric Jay
Halabi, Susan
Carducci, Michael Anthony
Ryan, Charles J.
George, Daniel J.
Mahoney, John Francis
Stadler, Walter Michael
Morris, Michael J.
Kantoff, Philip
Monk, J. P.
Kelly, William Kevin
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Duke Univ, Sch Med, Durham, NC USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[4] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[6] Duke Canc Inst, Durham, NC USA
[7] Carolinas Hematol Oncol Associates, Charlotte, NC USA
[8] Univ Chicago, Chicago, IL 60637 USA
[9] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA
[10] Dana Farber Canc Inst, Boston, MA 02115 USA
[11] Ohio State Univ, CALGB, Columbus, OH 43210 USA
[12] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4667
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401
    Kelly, W. K.
    Halabi, S.
    Carducci, M. A.
    George, D. J.
    Mahoney, J. F.
    Stadler, W. M.
    Morris, M. J.
    Kantoff, P. W.
    Monk, J. P., III
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [2] Serum androgens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance).
    Ryan, Charlesj.
    Dutta, Sandipan
    Kelly, William Kevin
    Middleberg, Rob
    Russell, Carly
    Small, Eric Jay
    Morris, Michael J.
    Taplin, Mary-Ellen
    Halabi, Susan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial
    Araujo, John C.
    Trudel, Geralyn C.
    Saad, Fred
    Armstrong, Andrew J.
    Yu, Evan Y.
    Bellmunt, Joaquim
    Wilding, George
    McCaffrey, John
    Serrano, Sergio V.
    Matveev, Vsevolod
    Efstathiou, Eleni
    Oudard, Stephane
    Morris, Michael J.
    Sizer, Bruce
    Goebell, Peter J.
    De Bono, Johann Sebastian
    Paliwal, Prashni
    Durham, Susan
    Cheng, Shinta
    Logothetis, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [4] Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC).
    Pond, Gregory Russell
    Armstrong, Andrew J.
    Wood, Brian A.
    Leopold, Lance Howard
    Galsky, Matt D.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [5] Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE).
    Patel, Jai Narendra
    Jiang, Chen
    Hertz, Daniel Louis
    Mulkey, Flora
    Friedman, Paula N.
    Halabl, Susan
    Rataln, Mark J.
    Morris, Michael J.
    Small, Eric Jay
    Owzar, Kouros
    Kelly, William Kevin
    McLeod, Howard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
    Kelly, William Kevin
    Halabi, Susan
    Carducci, Michael
    George, Daniel
    Mahoney, John F.
    Stadler, Walter M.
    Morris, Michael
    Kantoff, Philip
    Monk, J. Paul
    Kaplan, Ellen
    Vogelzang, Nicholas J.
    Small, Eric J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (13) : 1534 - 1540
  • [7] Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Adesunloye, Bamidele
    Huang, Xuan
    Ning, Yangmin M.
    Madan, Ravi A.
    Gulley, James L.
    Beatson, Melony
    Kluetz, Paul Gustav
    Adelberg, David
    Arlen, Philip M.
    Parnes, Howard L.
    Mulquin, Marcia
    Steinberg, Seth M.
    Wright, John Joseph
    Trepel, Jane B.
    Dawson, Nancy Ann
    Chen, Clara
    Apolo, Andrea Borghese
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [8] Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
    Azad, Arun
    Lester, Renee
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [9] Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial
    Sonpavde, Guru
    Pond, Gregory Russell
    Clarke, Stephen John
    Vardy, Janette L.
    Wang, S. L.
    Paolini, Jolanda
    Lechuga, Mariajose
    Michaelson, M. Dror
    Smith, Matthew Raymond
    Chen, Isan
    Maneval, Edna Chow
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Randomized phase II trial of abiraterone ± dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC).
    Dorff, Tanya B.
    Quinn, David I.
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan G.
    Kuhn, Peter
    Gross, Mitchell E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345